> Details

Gomber, Apoorva; Valeta, Francis; Coates, Matthew M; Trujillo, Celina; Ferrari, Gina; Boti, Medson; Kumwenda, Kenwood; Mailosi, Bright; Nakotwa, Dester; Drown, Laura; Wroe, Emily B; Thapa, Ada; Mithi, Victor; Matanje, Beatrice; Msekandiana, Amos; Park, Paul H; Kachimanga, Chiyembekezo; Bukhman, Gene; Ruderman, Todd; Adler, Alma J

Feasibility of continuous glucose monitoring in patients with type 1 diabetes at two district hospitals in Neno, Malawi: a randomised controlled trial

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Feasibility of continuous glucose monitoring in patients with type 1 diabetes at two district hospitals in Neno, Malawi: a randomised controlled trial
  • Contributor: Gomber, Apoorva; Valeta, Francis; Coates, Matthew M; Trujillo, Celina; Ferrari, Gina; Boti, Medson; Kumwenda, Kenwood; Mailosi, Bright; Nakotwa, Dester; Drown, Laura; Wroe, Emily B; Thapa, Ada; Mithi, Victor; Matanje, Beatrice; Msekandiana, Amos; Park, Paul H; Kachimanga, Chiyembekezo; Bukhman, Gene; Ruderman, Todd; Adler, Alma J
  • Published: BMJ, 2024
  • Published in: BMJ Open, 14 (2024) 5, Seite e075554
  • Language: English
  • DOI: 10.1136/bmjopen-2023-075554
  • ISSN: 2044-6055
  • Origination:
  • Footnote:
  • Description: ObjectivesTo assess the feasibility and change in clinical outcomes associated with continuous glucose monitoring (CGM) use among a rural population in Malawi living with type 1 diabetes.DesignA 2:1 open randomised controlled feasibility trial.SettingTwo Partners In Health-supported Ministry of Health-run first-level district hospitals in Neno, Malawi.Participants45 people living with type 1 diabetes (PLWT1D).InterventionsParticipants were randomly assigned to Dexcom G6 CGM (n=30) use or usual care (UC) (n=15) consisting of Safe-Accu glucose monitors and strips. Both arms received diabetes education.OutcomesPrimary outcomes included fidelity, appropriateness and severe adverse events. Secondary outcomes included change in haemoglobin A1c (HbA1c), acceptability, time in range (CGM arm only) SD of HbA1c and quality of life.ResultsParticipants tolerated CGM well but were unable to change their own sensors which resulted in increased clinic visits in the CGM arm. Despite the hot climate, skin rashes were uncommon but cut-out tape overpatches were needed to secure the sensors in place. Participants in the CGM arm had greater numbers of dose adjustments and lifestyle change suggestions than those in the UC arm. Participants in the CGM arm wore their CGM on average 63.8% of the time. Participants in the UC arm brought logbooks to clinic 75% of the time. There were three hospitalisations all in the CGM arm, but none were related to the intervention.ConclusionsThis is the first randomised controlled trial conducted on CGM in a rural region of a low-income country. CGM was feasible and appropriate among PLWT1D and providers, but inability of participants to change their own sensors is a challenge.Trial registration numberPACTR202102832069874.
  • Access State: Open Access